Overview

The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study

Status:
Completed
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in patients with Post-Infective Irritable Bowel Syndrome (PI-IBS). The investigators will evaluate gastrointestinal symptoms, IBS specific quality of life (IBS-QOL), and plasma cytokines before and after treatment with Lialda.
Phase:
Phase 3
Details
Lead Sponsor:
University of Utah
Collaborator:
Shire Human Genetic Therapies, Inc.
Treatments:
Mesalamine